In an AstraZeneca-developed training program, AI-assisted HER2 IHC scores had higher agreement with centrally confirmed scores.

Kicking off this week in Chicago, this year’s American Association for Cancer Research conference will feature presentations ...

In addition, AstraZeneca, Daiichi Sankyo, and the pan-Canadian Pharmaceutical Alliance (pCPA) have signed a Letter of Intent under the Temporary Access Process (pTAP). Together with the TLR, this ...

AstraZeneca (AZ) and Daiichi Sankyo (DS) are pleased to announce that Canada's Drug Agency (CDA, formerly CADTH) has issued a Time-Limited Reimbursement (TLR) recommendation – the first in gastric ...

Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new ...

Tumors with low- and ultra-low levels of a protein called HER2 are treatable with Enhertu, but harder to identify. New ...

Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 20 abstracts in multiple cancers at the 2025 American Society of Clinical Oncology Scientific ...

ZoomRx polled 50 experienced oncologists and hemato-oncologists about 20 cancer drugmakers, asking the doctors to rank the ...

UK pharma major AstraZeneca (LSE: AZN) is set to present data from more than 80 studies at the 2025 American Society of ...

The Immunotherapy Drugs Market is set to grow from USD 257.60 billion in 2024 to USD 486.36 billion by 2030, with a CAGR of ...

Anglo-Swedish pharma major AstraZeneca reports that it will have a historic presence at this year’s American Society of ...